Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment

Kent, Seamus; Burn, Edward; Dawoud, Dalia; Jónsson, Páll; Østby, Jens Torup; Hughes, Nigel; Bouvy, Jacoline C.

doi:10.1007/s40273-020-00981-9

Cited by 58 publications

(53 citation statements)

References 57 publications

(94 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It supports the access of multidatabase studies and translation of evidence across the individual hospitals and settings. The OMOP CDM applies standard vocabularies to normalize the meaning of data, such as Standard Nomenclature of Medicine (SNOMED) to represent clinical data, RxNorm to represent drugs, and Logical Observation Identifiers Names and Code (LOINC) to represent clinical measurements [ 12 ]. The CDM and open-source tools are opened on OHDSI GitHub ( https://github.com/OHDSI/ ), and discussions are opened on a dedicated open forum ( https://forums.ohdsi.org/ ).…”

Section: Methodsmentioning

confidence: 99%

Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model

Han

Son

Choi

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

Chronic kidney disease–mineral bone disorder (CKD-MBD) is the most common complication in CKD patients. Although there is a consensus on treatment guidelines for CKD-MBD, it remains uncertain whether these treatment recommendations reflect actual practice. Therefore, the aim of this study was to investigate the CKD-MBD medication trend in real-world practice. This was a retrospective and observational study using a 12-year period database transformed into a common data model from three tertiary university hospitals. Study populations were subjects initially diagnosed as CKD. The date of diagnosis was designated as the index date. New patients were categorized year to year from 2008 to 2019 with a fixed observation period of 365 days to check the prescription of CKD-MBD medications including calcium-containing phosphate binder, noncalcium-containing phosphate binder, aluminium hydroxide, vitamin D receptor activator (VDRA), and cinacalcet. The numbers of CKD patients in the three hospitals were 7555, 2424, and 5351, respectively. The proportion for patients with CKD-MBD medication prescription decreased yearly regardless of hospital and CKD stage ( p for trend < 0.05). The use of aluminium hydroxide disappeared steadily while the use of VDRA increased annually in all settings. Despite these changes in prescription patterns, the mean value for CKD-MBD-related serologic markers was almost within target range. The proportion of the population within the target value was not significantly changed. Irrespective of hospital and CKD stage, similar trends of prescription for CKD-MBD medications were observed in real-world practice. Further research with a distributed network study may be helpful to understand medication trends in CKD-MBD treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model

Han

Son

Choi

et al. 2021

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Routinely collected real world data (RWD) are a powerful asset for an evolving pandemic response [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…

…”

mentioning

confidence: 99%

“…Background: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response [1,2]. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) [3] Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS

Prieto-Alhambra

Kostka

Duarte‐Salles

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Routinely collected real world data (RWD) have great utility in aiding the novel coronavirus disease (COVID-19) pandemic response [1,2]. Here we present the international Observational Health Data Sciences and Informatics (OHDSI) [3] Characterizing Health Associated Risks, and Your Baseline Disease In SARS-COV-2 (CHARYBDIS) framework for standardisation and analysis of COVID-19 RWD.Methods: We conducted a descriptive cohort study using a federated network of data partners in the United States, Europe (the Netherlands, Spain, the UK, Germany, France and Italy) and Asia (South Korea and China). The study protocol and analytical package were released on 11th June 2020 and are iteratively updated via GitHub [4]. Findings: We identified three non-mutually exclusive cohorts of 4,537,153 individuals with a clinical COVID-19 diagnosis or positive test, 886,193 hospitalized with COVID-19, and 113,627 hospitalized with COVID-19 requiring intensive services. All comorbidities, symptoms, medications, and outcomes are described by cohort in aggregate counts, and are available in an interactive website: https://data.ohdsi.org/Covid19CharacterizationCharybdis/. Interpretation: CHARYBDIS findings provide benchmarks that contribute to our understanding of COVID-19 progression, management and evolution over time. This can enable timely assessment of real-world outcomes of preventative and therapeutic options as they are introduced in clinical practice.

show abstract

“…CDM standardizes data inputs from various sources and facilitates data integration minimizing time and cost-related in conducting observational studies. ( Kent et al, 2021 )…”

Section: Introductionmentioning

confidence: 99%

Covid-19 Vaccine Surveillance in Saudi Arabia: Opportunities for Real-time Assessment

Albogami

Alkofide

Alrwisan

2021

Saudi Pharmaceutical Journal

View full text Add to dashboard Cite

After months of confronting COVID-19 pandemic, several countries, including Saudi Arabia, have recently approved newly developed vaccines to prevent COVID-19 infection. With the new technology utilized to develop some vaccines, questions arise about their long-term safety. To provide rapid response to emerging safety issues, robust surveillance programs that provide near real-time analysis of vaccines effects are required. Saudi Arabia has a well-established passive pharmacovigilance system that monitors drugs and vaccines safety. However, recent development in health digitalization in Saudi Arabia may provide a unique opportunity to harvest existing resources to generate high-quality evidence. This commentary provides an overview of the available systems that can be utilized to monitor the COVID-19 vaccines’ safety and discusses opportunities for data integration to improve data quality and generate real-world evidence on COVID-19 vaccine safety.

show abstract

Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment

Cited by 58 publications

References 57 publications

Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model

Characterization of Medication Trends for Chronic Kidney Disease: Mineral and Bone Disorder Treatment Using Electronic Health Record-Based Common Data Model

Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS

Covid-19 Vaccine Surveillance in Saudi Arabia: Opportunities for Real-time Assessment

Contact Info

Product

Resources

About